Demcizumab, CAS 1243262-17-0

Product Description: Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models[1][2][3].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Smith DC, et al. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clin Cancer Res. 2014 Dec 15;20(24):6295-303. /[2]Fischer M, et al. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res 2011;71:1520-5. /[3]Hoey T, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009;5:168–77. /[4]Xiong H, et al. Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia. Theranostics. 2021 Jan 1;11(4):1594-1608.

CAS Number: 1243262-17-0

Molecular Weight: 145.65 (kDa)

Compound Purity: 95.0

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: Notch

• Artikelnummer: MEXHY-P99261-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99261-5
• Green Labware: Nein
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK